On April 30, 2018 Inovio Pharmaceuticals, Inc. (NASDAQ:INO) reported that it will host a conference call and live webcast to report its 2018 first quarter financial results on Wednesday, May 9, 2018 at 4:30 p.m. ET (Press release, Inovio, APR 30, 2018, View Source [SID1234525832]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live and archived version of the audio presentation will be available online at View Source This is a listen-only event but will include a live Q&A with analysts.

A replay of the conference call will be accessible two hours after the call at 877-481-4010 (domestic) or 919-882-2331 (international) using replay ID 29009.

On April 30, 2018 Array BioPharma Inc. (Nasdaq: ARRY) reported that it will report financial results for the third quarter of fiscal 2018 and hold a conference call to discuss those results on Wednesday, May 9, 2018 (Press release, Array BioPharma, APR 30, 2018, View Source;p=RssLanding&cat=news&id=2345678 [SID1234525849]). Ron Squarer, Chief Executive Officer, will lead the call.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Wednesday, May 9, 2018

Time: 9:00 a.m. Eastern Time

Toll-Free: (844) 464-3927

Toll: (765) 507-2598

Pass Code: 6465079

Webcast, including Replay and Conference Call Slides:
View Source

On April 30, 2018 McKesson Corporation (NYSE:MCK) reported that it will release financial results for its fourth fiscal quarter ended March 31, 2018 on Thursday, May 24, 2018, prior to the opening of trading on the New York Stock Exchange (Press release, McKesson, APR 30, 2018, View Source [SID1234525868]). The company has scheduled a conference call for 8:00 AM Eastern Time (5:00 AM Pacific Time), during which John Hammergren, chairman and chief executive officer, and Britt Vitalone, executive vice president and chief financial officer, will review these results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The dial-in number for individuals wishing to participate on the call is 323-701-0225. Craig Mercer, senior vice president, Investor Relations is the leader of the call and the password is ‘McKesson’. The conference call will also be available live and archived on the company’s Investor Relations website at View Source

On April 27, 2018 Compugen Ltd. (Nasdaq: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, reported that the U.S. Food and Drug Administration (FDA) requested that the Company provide additional CMC information in support of its IND application for COM701, initially submitted in late March 2018 (Press release, Compugen, APR 27, 2018, View Source [SID1234525792]). COM701 is a first-in-class immuno-oncology therapeutic antibody targeting PVRIG. FDA recommended a lower starting dose of COM701 for the trial, which now requires a more sensitive COM701 assay detection method for this dose. The FDA informed the Company that the IND application review can be completed and the application can be taken off clinical hold once the requested information is provided by Compugen. The IND is intended to support initiation of a planned Phase 1 clinical trial of COM701 in patients with advanced solid tumors. This trial is not yet active at any investigational sites and has not recruited any patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are working closely with the FDA to provide the additional information requested as quickly as possible. In anticipation for FDA clearance, site selection activities in multiple centers in the United States are currently ongoing to allow future patient enrollment, and we look forward to evaluating COM701 in a clinical setting," stated Anat Cohen-Dayag, PhD, President and CEO of Compugen. "We continue to be encouraged by the preclinical data for COM701, which suggest that targeting PVRIG may be a primary means of stimulating an anti-tumor immune response in certain cancers that may be unresponsive to available treatments."

The Company will continue to provide updates on this matter as appropriate.

On April 27, 2018 Haihe Biopharma Co., Ltd. and 3D Medicines (Beijing) Co., Ltd. reported that the two sides have reached a strategic collaboration agreement on HaiHe Biopharma’s FGFR inhibitor (coded HH185) project (Press release, 3D Medicines, APR 27, 2018, View Source [SID1234594049]). 3DMed may carry out the R&D, manufacture and commercialization of HH185 in mainland China, Hong Kong, Macao and Taiwan for the treatment of cancer and pulmonary fibrosis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Ruiping Dong, CEO of Haihe Biopharma, commented,
"As a potential target in the field of anti-tumor, FGFR is undergoing rapid development in the research of its mechanisms and clinical application and more and more verifications has been made. Therefore, the R&D prospect is so promising. As a highly selective FGFR inhibitor, HH185 overcomes the adverse effect of hepatotoxicity found in the first-generation FGFR inhibitor and has the apparent anti-tumor activity. We look forward to working together with 3DMed on the further development and commercialization of HH185, so as to accelerate the launch of the domestically-manufactured new drugs and to meet the patients’ needs in China."

Dr. Gong Zhaolong, CEO of 3D Med, commented,
"We are very happy to reach the strategic collaboration agreement with HaiHe Biopharma on HH185.HH185 has a good prospect of combination with 3DMed’s PD-L1 antibody in the field of immuno-oncology therapy. Through the collaboration with HaiHe Biopharma and by virtue of 3DMed’s platform and experience in the field of precision cancer care, we hope to be able to develop new drugs that are urgently needed in clinical practice for the benefit of even more patients who suffer from cancer and pulmonary fibrosis."

About HH185
HH185 is a small molecule inhibitor of fibroblast growth factor receptor 1,2,3 (FGFR 1,2,3), which obtained the approval for clinical trial by CNDA in January 2018. Preclinical studies have shown that HH185 has such advantages as strong anti-tumor activity, excellent PD-PK characteristics, low toxicity and high bioavailability and so on. Moreover, it is targeting CSF1-R and is therefore suitable for combination therapy with PD-1/PD-L1 antibodies in the field ofimmune-oncology.